Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2010

View Archived Issues

Encouraging phase I data disclosed on phIL-12-005/PPC in recurrent ovarian cancer

Novartis claims new inhibitors of SGLT-1 and SGLT-2

Roche presents new dual 5-HT2A and dopamine D3 receptors modulators

Karo Bio identifies novel estrogen receptor beta ligands

Merck Frosst claims new prostanoid DP2 receptor antagonists

Swedish scientists claim new SSAO inhibitors

ChemoCentryx identifies new CMKLR1 receptor antagonist

Preliminary data disclosed from long-term safety/efficacy phase III trial of LibiGel in HSDD

Almirall presents new DHODH inhibitors suitable for clinical development

Bazedoxifene shows potential as endometriosis therapy in preclinical study

Clinical data disclosed on avosentan in overt diabetic nephropathy

Janssen-Ortho discontinues sale of ceftobiprole in Canada

Clinical data disclosed on lamotrigine in secondary progressive multiple sclerosis

Teva's Copaxone reaches one million patient years of experience in multiple sclerosis

Affinium begins phase I trial of new antistaphylococcal antibiotic AFN-1252

Medinox and Orient Europharma partner for antihypotensive drug NOX-100

Alkermes submits Vivitrol sNDA in U.S. for opioid dependence

Israeli government awards grant to Prolor Biotech for longer-acting human growth hormone

PharmaSurgics' phase II PXL-01 trial extended to Denmark

Arecor and Genzyme join to develop advanced therapeutic protein formulations

RXi and Mirna Therapeutics form microRNA research collaboration

FDA approves Sinapis' methamphetamine IND for stroke

Sanofi Pasteur and U.S. Naval Medicine Center partner to develop travelers' diarrhea vaccine

FDA approves Johnson & Johnson's Pancreaze delayed-release capsules

Aushon launches multiplex biomarker panels to aid measurement of vascular injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...